Devyser Diagnostics
111,5 SEK +1,36%1 investor følger denne virksomhed
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
DVYSR
Daglig lav / høj pris
108,5 / 112
SEK
Markedsværdi
1,84 mia. SEK
Aktieomsætning
420,99 t SEK
Volumen
3,8 t
Seneste videoer
Finanskalender
Delårsrapport
30.10.2024
Årsrapport
13.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Rutger Arnhult, via bolag | 24,2 % | 24,2 % |
Nordnet Pensionsförsäkringar | 8,3 % | 8,3 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Devyser Diagnostics AB publishes quarterly report for the period April to June 2024
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools